The antibiotic minocycline increases the lifespan of aged roundworms and prevents the buildup of proteins, revealing a protective mechanism that could be exploited therapeutically to help prevent neurodegenerative diseases.
Now, scientists at Scripps Research have found that minocycline can increase the lifespan of roundworms by preventing the buildup of proteins during aging, according to a study in the open-access journal eLife reports.
Protein aggregation causes several progressive age-related brain diseases, including amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s and prion diseases. The Scripps Research study shows that minocycline prevents this buildup even in older animals with age-impaired stress-response pathways.
The number of proteins in a cell is balanced by the rate of protein manufacture and disposal, called proteostasis. As we age, proteostasis becomes impaired.
“It would be great if there were a way to enhance proteostasis and extend lifespan and health, by treating older people at the first sign of neurodegenerative symptoms or disease markers such as protein build-up,” says lead author Gregory Solis, a graduate student at Scripps Research. “In this study, we investigated whether minocycline can reduce protein aggregation and extend lifespan in animals that already have impaired proteostasis.”
The team first tested 21 different molecules known to extend lifespan in young and old Caenorhabditis elegans (C. elegans) worms. They found that all of these molecules prolonged the lives of young worms, however, the only drug that worked on the older worms was minocycline.
To find out why, the researchers looked at whether minocycline had any effect on protein aggregation in the worms. They treated young and old worms with water or minocycline and then measured two proteins, ?-synuclein and amyloid-?, which are known to build up in Parkinson’s and Alzheimer’s, respectively. Regardless of the worms’ age, those treated with minocycline had reduced aggregation of both proteins as they grew older.
The team next turned their attention to the mechanism behind this discovery. First, they looked at whether minocycline switches on stress-signaling proteins that are impaired in older worms, but they found the drug actually reduces their activity. Next, they studied whether it turns off the cell’s protein-disposal processes, but this was not its mode of action either.
When researchers used a chemical probe to see how minocycline affects the major protein-regulating molecules in the cell, it revealed that minocycline directly affects the protein-manufacturing machinery of the cell, known as the ribosome. This was true in worms, as well as in mouse and human cells.
Finally, the team used worms with increased or decreased protein-manufacturing activity and studied how this altered the effect of minocycline on protein levels and lifespan. As predicted, in mutant worms where protein manufacturing was already decreased, they found a lower dose of minocycline was needed to further reduce protein levels and extend lifespan. In worms where protein manufacturing was increased, the opposite was seen. This suggested that minocycline extends lifespan by controlling the rate of protein manufacturing at the ribosome.
“We have identified minocycline as a drug that can extend lifespan and improve protein balance in already-aging worms,” says Michael Petrascheck, PhD, senior author of the paper and associate professor at Scripps Research. “Our study reveals how minocycline prevents protein aggregation and lays the foundations for drug development efforts aimed at optimizing this already-approved drug for a range of neurodegenerative diseases.”
The Latest on: Minocycline
via Google News
The Latest on: Minocycline
- VYNE Therapeutics Inc. (VYNE) Q4 2020 Earnings Call Transcripton March 4, 2021 at 10:30 am
Q4 2020 Earnings CallMar 04, 2021, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning and welcome to the VYNE Therapeutics ...
- VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Updateon March 4, 2021 at 4:00 am
VYNE Therapeutics Inc. today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.. ZILXI ® topical foam, 1.5%, for the treatment of ...
- Global Minocycline Hydrochloride Market Size, Growth, Share 2021 (Volume and Value) And, to 2024 this Information in Latest Researchon February 21, 2021 at 4:20 pm
Global Minocycline Hydrochloride Market Report 2021 -2024 contains systematic and point to point information regarding to Minocycline Hydrochloride Market Size. The report contains brief Introduction, ...
- Hovione Announces Successful End-of-phase 2 Meeting With the FDA and Outlines Phase 3 Program for Minocycline Topical Gelon February 20, 2021 at 4:00 pm
CORK, Ireland, Sept. 20, 2019 /PRNewswire/ -- Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of ...
- Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosison February 17, 2021 at 4:00 pm
On the basis of encouraging preliminary results, we conducted a randomized, controlled trial to determine whether minocycline reduces the risk of conversion from a first demyelinating event (also ...
- An Open-label Pilot Trial of Minocycline in Children as a Treatment for Angelman Syndromeon February 10, 2021 at 4:00 pm
However, this has not precluded the investigation of minocycline (with associated benefit) on human neurological diseases such as Alzheimer's, Parkinson's, Stroke, traumatic brain injuries and ...
- An Open-label Pilot Trial of Minocycline in Children as a Treatment for Angelman Syndromeon February 7, 2021 at 4:00 pm
Background Minocycline, a member of the tetracycline family, has a low risk of adverse effects and an ability to improve behavioral performance in humans with cognitive disruption. We performed a ...
- VYNE Therapeutics Announces FDA Approval of AMZEEQ (Minocycline) Label Updateon February 1, 2021 at 9:29 am
AMZEEQ label update includes new information indicating the low propensity of Propionibacterium acnes (more commonly known as “P. acnes”) to develop resistance to minocycline BRIDGEWATER, N.J ...
- VYNE Therapeutics Announces FDA Approval of AMZEEQ(R) (Minocycline) Label Updateon February 1, 2021 at 12:00 am
acnes strains to develop resistance to minocycline, the active ingredient in AMZEEQ. AMZEEQ is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris ...
- HEALTH NOTES: Antibiotics 'help treat depression'on January 30, 2021 at 8:22 pm
Doctors at South London and Maudsley NHS Foundation recruited 39 patients suffering 'treatment-resistant' depression and gave half of them the antibiotic minocycline. While not all of them ...
via Bing News